TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15972086

Group type: EXPERIMENTAL
Intervention: Zonisamide (540 mg/day during maintenance phase)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 12709185

Group type: EXPERIMENTAL
Intervention: Pharmacist facilitated teaching session
Number of subjects: 40

Group type: COMPARATOR
Intervention: No additional teaching (Control)
Number of subjects: 40
Study: 10505585

Group type: EXPERIMENTAL
Intervention: Olanzapine 10 mg for 3 to 5 days
Number of subjects: 106

Group type: COMPARATOR
Intervention: Placebo for 3 to 5 days
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Open-label olanzapine (10-25 mg/day) for 9 weeks
Number of subjects: 106
Study: 7545986

Group type: EXPERIMENTAL
Intervention: Cue-exposure intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no cue-exposure sessions)
Number of subjects: 0
Study: 1669122

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Acebutolol
Number of subjects: 48

Group type: COMPARATOR
Intervention: Both drugs
Number of subjects: 48
Study: 7006561

Group type: EXPERIMENTAL
Intervention: Surgery followed by cyclophosphamide (100 mg/kg BW in daily intravenous doses of 200 mg)
Number of subjects: 372

Group type: EXPERIMENTAL
Intervention: Preoperative radiation therapy (about 5500 rad tumour dose by telecobalt) and surgery
Number of subjects: 372

Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 372
Study: 31819948

Group type: EXPERIMENTAL
Intervention: Radiotherapy alone
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Radiotherapy combined with chemotherapy and/or thermotherapy
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: High HPV viral load
Number of subjects: 62
Study: 31399033

Group type: EXPERIMENTAL
Intervention: Liraglutide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 27352956

Group type: EXPERIMENTAL
Intervention: High onion group (HO; n = 28) - 100 to 160 g/d of onion for 8 weeks
Number of subjects: 56

Group type: COMPARATOR
Intervention: Low onion group (LO; n = 28) - 30 to 40 g/d small onions for 8 weeks
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: High onion group (HO; n = 28)
Number of subjects: 56
Study: 25652804

Group type: EXPERIMENTAL
Intervention: Electroacupuncture plus usual care
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care only
Number of subjects: 0
Study: 24054337

Group type: EXPERIMENTAL
Intervention: Nesiritide
Number of subjects: 7141

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7141
Study: 20960436

Group type: EXPERIMENTAL
Intervention: Apomorphine
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 19642002

Group type: COMPARATOR
Intervention: Non-white immigrants
Number of subjects: 5464

Group type: COMPARATOR
Intervention: White male immigrants
Number of subjects: 5464

Group type: EXPERIMENTAL
Intervention: Canadian born individuals
Number of subjects: 5464

Group type: EXPERIMENTAL
Intervention: White immigrants
Number of subjects: 5464
Study: 17431101

Group type: EXPERIMENTAL
Intervention: Investigational agent (growth-inhibitory drug) during the run-in period, followed by randomization to continue or discontinue therapy.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (control group) during the double-blind phase after the run-in period.
Number of subjects: 0
Study: 15173844

Group type: COMPARATOR
Intervention: 0 mg intravenous delta-9-tetrahydrocannabinol (Delta-9-THC)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: 2.5 mg intravenous delta-9-tetrahydrocannabinol (Delta-9-THC)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: 5 mg intravenous delta-9-tetrahydrocannabinol (Delta-9-THC)
Number of subjects: 22
Study: 11224687

Group type: EXPERIMENTAL
Intervention: 5-Azacytidine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hydroxyurea
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Butyrates
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination therapy (Butyrates + Hydroxyurea)
Number of subjects: 0
Study: 9138198

Group type: EXPERIMENTAL
Intervention: Group-based behavior modification intervention consisting of 5 weekly, 90-min sessions including skill training, self-monitoring, weekly feedback, and group support
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Group-based behavior modification intervention
Number of subjects: 107

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 107
Study: 7949260

Group type: EXPERIMENTAL
Intervention: Dietary supplementation of biscuits containing raw fibre and lactulose (Fiberlac, Bracco)
Number of subjects: 10
Study: 2975091

Group type: EXPERIMENTAL
Intervention: Verapamil (1 mg intracoronarily)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (intracoronarily)
Number of subjects: 20
Study: 29430970

Group type: EXPERIMENTAL
Intervention: Pain Exposure Physical Therapy (maximum of five sessions)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Conventional treatment conforming with the Dutch multidisciplinary guideline
Number of subjects: 56
Study: 28529951

Group type: EXPERIMENTAL
Intervention: UCMCs transfusion
Number of subjects: 63

Group type: COMPARATOR
Intervention: Control group (without transplantation)
Number of subjects: 63
Study: 26232133

Group type: EXPERIMENTAL
Intervention: Olmesartan with conventional or intensive diet education
Number of subjects: 229
Study: 23941670

Group type: COMPARATOR
Intervention: 2.5 g/kg/day of amino acids (standard AA [SAA] group)
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: 4 g/kg/day of amino acids (high AA [HAA] group)
Number of subjects: 131

Group type: COMPARATOR
Intervention: 2.5 g/kg/day of amino acids (SAA group)
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: 4 g/kg/day of amino acids (HAA group)
Number of subjects: 131

Group type: COMPARATOR
Intervention: Body weight, length, and head circumference at 36 weeks
Number of subjects: 131

Group type: COMPARATOR
Intervention: Bayley Scales of Infant and Toddler Development, Third Edition score in SAA group
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Bayley Scales of Infant and Toddler Development, Third Edition score in HAA group
Number of subjects: 131
Study: 21923847

Group type: EXPERIMENTAL
Intervention: Insulin detemir (long-acting analogue; LAA)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 70% insulin aspart protamine and 30% insulin aspart (biphasic insulin analogue; BIA)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Twice-daily BIA therapy
Number of subjects: 120
Study: 19808287

Group type: EXPERIMENTAL
Intervention: Conventional treatment and device-guided paced breathing (n=12)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Conventional treatment (n=12)
Number of subjects: 24
Study: 16478629

Group type: EXPERIMENTAL
Intervention: CIAIV‐CCRT (intraarterial cisplatin/nedaplatin and intravenous 5-fluorouracil)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group (radiation therapy alone)
Number of subjects: 45
Study: 12882847

Group type: EXPERIMENTAL
Intervention: Candesartan 16 mg daily
Number of subjects: 20

Group type: COMPARATOR
Intervention: ACEI alone (lisinopril/enalapril 40 mg daily or captopril 150 mg daily)
Number of subjects: 20
Study: 11056590

Group type: EXPERIMENTAL
Intervention: HIV‐1 Immunogen
Number of subjects: 2527

Group type: COMPARATOR
Intervention: Placebo (incomplete Freund adjuvant)
Number of subjects: 2527

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 2527
Study: 8791245

Group type: EXPERIMENTAL
Intervention: 3,4-Diaminopyridine (DAP)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 1463179

Group type: EXPERIMENTAL
Intervention: General anaesthesia plus thoracic epidural blockade with 0.5% bupivacaine
Number of subjects: 20

Group type: COMPARATOR
Intervention: General anaesthesia alone
Number of subjects: 20
Study: 6388424

Group type: EXPERIMENTAL
Intervention: Isoxsuprine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 31196142

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 28805468

Group type: EXPERIMENTAL
Intervention: Single-pill fixed-dose combination therapy
Number of subjects: 12433

Group type: COMPARATOR
Intervention: Two-pills combination therapy
Number of subjects: 12433
Study: 26373701

Group type: EXPERIMENTAL
Intervention: High-carbohydrate diet
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Moderate-carbohydrate diet
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Low-carbohydrate diet
Number of subjects: 21
Study: 23851000

Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy (CBT) (N=30)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Child-Centered Therapy (CCT) (N=17)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Pre-treatment encouragement of bravery
Number of subjects: 67
Study: 21877998

Group type: EXPERIMENTAL
Intervention: DHEA 50 mg q.d. for 4 months
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo for 4 months
Number of subjects: 12
Study: 19722442

Group type: EXPERIMENTAL
Intervention: Phosphoric acid (Group 1)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Phosphoric acid and a single-bottle dentin bonding agent (Group 2)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Self-etching adhesive (Group 3)
Number of subjects: 60
Study: 18086056

Group type: EXPERIMENTAL
Intervention: NASHA (Restylane and/or Perlane, mean dosage 69 mg)
Number of subjects: 433
Study: 15263832

Group type: EXPERIMENTAL
Intervention: Adrenalin 0.1 mg with 10 ml 0.9% NaCl (1/100,000 dilution)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Physiological serum solution
Number of subjects: 51
Study: 11427321

Group type: EXPERIMENTAL
Intervention: Intramuscular infusion of 0.5 ml hypertonic saline (6%) into the tibialis anterior muscle
Number of subjects: 14
Study: 9708870

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 7820712

Group type: EXPERIMENTAL
Intervention: Rapid instillation of Exosurf (5 minutes)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Slow instillation of Exosurf (15 minutes)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Both groups (Rapid and Slow)
Number of subjects: 27
Study: 3344411

Group type: EXPERIMENTAL
Intervention: APD 30 mg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: APD 45 mg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: APD 60 mg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: APD 90 mg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: APD (all doses)
Number of subjects: 40
Study: 29957150

Group type: EXPERIMENTAL
Intervention: Telemedicine (telepresent senior physician team leader)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Usual care (both physicians in the room)
Number of subjects: 20
Study: 28166253

Group type: EXPERIMENTAL
Intervention: Very high saturated fat diet (HSF; 39%E carbohydrate, 25%E protein, 36%E fat, 18%E saturated fat)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Very high saturated fat diet (HSF)
Number of subjects: 53
Study: 25478757

Group type: EXPERIMENTAL
Intervention: Ultrasound guidance
Number of subjects: 50

Group type: COMPARATOR
Intervention: Fluoroscopy guidance
Number of subjects: 50
Study: 23497760

Group type: EXPERIMENTAL
Intervention: Empagliflozin 25 mg alone
Number of subjects: 59

Group type: COMPARATOR
Intervention: Empagliflozin 25 mg with verapamil 120 mg
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Empagliflozin 25 mg QD for 5 days with ramipril (2.5 mg on day 1 then 5 mg QD on days 2‐5)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Ramipril (2.5 mg on day 1 then 5 mg QD on days 2‐5)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Empagliflozin 25 mg QD for 8 days with single‐dose digoxin 0.5 mg on day 5
Number of subjects: 59

Group type: COMPARATOR
Intervention: Single‐dose digoxin 0.5 mg alone
Number of subjects: 59
Study: 22050797

Group type: EXPERIMENTAL
Intervention: Oral atenolol 50 mg twice daily for one day prior to surgery (Group I)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Intraoperative nitroprusside infusion (Group II)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Intraoperative esmolol infusion (Group III)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Atenolol and esmolol groups
Number of subjects: 105

Group type: COMPARATOR
Intervention: All groups
Number of subjects: 105
Study: 18435833

Group type: EXPERIMENTAL
Intervention: Erythromycin 250 mg
Number of subjects: 9075

Group type: EXPERIMENTAL
Intervention: Co-amoxiclav 375 mg
Number of subjects: 9075

Group type: COMPARATOR
Intervention: Antibiotics (general)
Number of subjects: 9075

Group type: EXPERIMENTAL
Intervention: Parental questionnaire
Number of subjects: 9075

Group type: EXPERIMENTAL
Intervention: National standard test results
Number of subjects: 9075
Study: 17310784

Group type: EXPERIMENTAL
Intervention: Moxifloxacin (Avelox) 400 mg every 24 hours, first intravenously then orally, for a total treatment duration of 7 to 12 days (average 8.45 ± 1.53 days).
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Moxifloxacin treatment.
Number of subjects: 22
Study: 12932070

Group type: EXPERIMENTAL
Intervention: Atorvastatin (standard doses for at least 4 months)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control (no atorvastatin)
Number of subjects: 15
Study: 10698243

Group type: EXPERIMENTAL
Intervention: Telephone messages followed by letters (Group A)
Number of subjects: 1227

Group type: EXPERIMENTAL
Intervention: Telephone messages alone (Group B)
Number of subjects: 1227

Group type: EXPERIMENTAL
Intervention: Letters only (Group C)
Number of subjects: 1227

Group type: COMPARATOR
Intervention: No notification (Group D)
Number of subjects: 1227

Group type: EXPERIMENTAL
Intervention: Any of the interventions (Groups A, B, C)
Number of subjects: 1227
Study: 9120965

Group type: EXPERIMENTAL
Intervention: Intravesical morphine 0.05 mg/ml
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Intravesical morphine 0.375 mg/ml
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Intravesical morphine 0.5 mg/ml
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control group (no morphine infusion)
Number of subjects: 52
Study: 8439215

Group type: EXPERIMENTAL
Intervention: MCT emulsion
Number of subjects: 18

Group type: COMPARATOR
Intervention: LCT emulsion
Number of subjects: 18
Study: 3531226

Group type: EXPERIMENTAL
Intervention: Cold-recombinant influenza A/California/10/78 (H1N1) (CR37)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Cold-recombinant influenza A/Washington/897/80 (H3N2) (CR48)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Inactivated trivalent influenza virus vaccine (administered parenterally)
Number of subjects: 40
Study: 30068630

Group type: EXPERIMENTAL
Intervention: 4.5-lb weight stimulus
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 2-lb weight stimulus
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 0-lb weight stimulus
Number of subjects: 36
Study: 26845739

Group type: EXPERIMENTAL
Intervention: bivalent rLP2086
Number of subjects: 5712

Group type: COMPARATOR
Intervention: HAV/saline
Number of subjects: 5712
Study: 23560678

Group type: EXPERIMENTAL
Intervention: d‐PTFE membrane (test)
Number of subjects: 23

Group type: COMPARATOR
Intervention: e‐PTFE membrane (control)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Both d‐PTFE and e‐PTFE membranes
Number of subjects: 23
Study: 22389254

Group type: EXPERIMENTAL
Intervention: Ofatumumab (CD20 mAb; dose 1, 300 mg and doses 2-8, 500 or 1000 mg)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Ofatumumab (CD20 mAb)
Number of subjects: 116
Study: 20039397

Group type: EXPERIMENTAL
Intervention: Rituximab plus MTX for 36 weeks
Number of subjects: 103

Group type: COMPARATOR
Intervention: MTX alone for 12 weeks
Number of subjects: 103
Study: 18533410

Group type: EXPERIMENTAL
Intervention: Percutaneous electrostimulation of the perineum (PESP)
Number of subjects: 18
Study: 15777291

Group type: EXPERIMENTAL
Intervention: Intravenous remifentanil (0.4 microg kg(‐1) PCA doses)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Nitrous oxide (50% inhaled)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Preference between remifentanil and nitrous oxide
Number of subjects: 20
Study: 12548058

Group type: EXPERIMENTAL
Intervention: Viable Lactobacillus GG
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Heat-inactivated Lactobacillus GG
Number of subjects: 35

Group type: COMPARATOR
Intervention: Extensively hydrolyzed whey formula (placebo group)
Number of subjects: 35
Study: 10625166

Group type: COMPARATOR
Intervention: Macintosh laryngoscope
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Bizzarri-Giuffrida laryngoscope
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Improved Vision Macintosh laryngoscope
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Wiemers laryngoscope
Number of subjects: 24
Study: 7730723

Group type: EXPERIMENTAL
Intervention: Minocycline 200 mg daily
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Minocycline 100 mg daily
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Minocycline 100 mg daily (after 5 months of treatment)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Minocycline (100 mg daily for 5 months)
Number of subjects: 12
Study: 2147912

Group type: EXPERIMENTAL
Intervention: Cetirizine
Number of subjects: 47

Group type: COMPARATOR
Intervention: Astemizole
Number of subjects: 47
Study: 32941

Group type: EXPERIMENTAL
Intervention: Oral androgen (27 patients)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Intrasmuscular androgen (23 patients)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: No androgen (13 patients)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Marrow transplantation (47 patients)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Supportive care (non-transplanted patients)
Number of subjects: 110
Study: 31812585

Group type: EXPERIMENTAL
Intervention: Fastballs
Number of subjects: 12

Group type: COMPARATOR
Intervention: Curveballs
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: BMI
Number of subjects: 12
Study: 30501389

Group type: EXPERIMENTAL
Intervention: Manual physical therapy (3 sessions including desensitization maneuvers)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Surgery (decompression/release of the carpal tunnel)
Number of subjects: 120
Study: 27190349

Group type: EXPERIMENTAL
Intervention: Research priorities identified through a national survey and workshop
Number of subjects: 439
Study: 25529596

Group type: EXPERIMENTAL
Intervention: Benazepril + Amlodipine (B+A)
Number of subjects: 11499

Group type: COMPARATOR
Intervention: Benazepril + Hydrochlorothiazide (B+H)
Number of subjects: 11499
Study: 23997699

Group type: EXPERIMENTAL
Intervention: Swift FX nasal pillows
Number of subjects: 21

Group type: COMPARATOR
Intervention: Nasal masks
Number of subjects: 21
Study: 21982052

Group type: EXPERIMENTAL
Intervention: Educational intervention including oral and written explanations about cardiac rehabilitation, a follow-up telephone call, and a seminar for medical staff.
Number of subjects: 1024

Group type: COMPARATOR
Intervention: Usual care without additional treatment.
Number of subjects: 1024
Study: 19729418

Group type: EXPERIMENTAL
Intervention: Intervention (4 standard consultations over 12 weeks targeting change in nutrition, physical activity, and sedentary behaviour)
Number of subjects: 258

Group type: EXPERIMENTAL
Intervention: Intervention
Number of subjects: 258

Group type: COMPARATOR
Intervention: Control
Number of subjects: 258
Study: 17760243

Group type: EXPERIMENTAL
Intervention: Lornoxicam (16 mg IV before surgery, 8 mg at 12h and 24h postoperatively)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Morphine with PCA (Control Group M)
Number of subjects: 46
Study: 15201414

Group type: EXPERIMENTAL
Intervention: Rituximab plus methotrexate
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Rituximab plus cyclophosphamide
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Rituximab (all groups)
Number of subjects: 161

Group type: COMPARATOR
Intervention: Control (methotrexate alone)
Number of subjects: 161
Study: 14706898

Group type: EXPERIMENTAL
Intervention: Herceptin®
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clinical studies (randomized trials, non-randomized studies, observational studies)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Modelization techniques
Number of subjects: 0
Study: 10194739

Group type: EXPERIMENTAL
Intervention: Higher methadone doses
Number of subjects: 265

Group type: COMPARATOR
Intervention: Lower methadone doses
Number of subjects: 265

Group type: EXPERIMENTAL
Intervention: Assigned therapist
Number of subjects: 265
Study: 7554793

Group type: EXPERIMENTAL
Intervention: Visual habituation study
Number of subjects: 0
Study: 2258583

Group type: EXPERIMENTAL
Intervention: Acipimox 500 mg
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 6447999

Group type: EXPERIMENTAL
Intervention: 5-hydroxytryptophan
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: pyridoxine hydrochloride
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Combination of 5-hydroxytryptophan and pyridoxine
Number of subjects: 89

Group type: COMPARATOR
Intervention: Control group (children with moderate and severe congenital heart disease excluded)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Various groups (including those whose parents complied with guidance)
Number of subjects: 89
Study: 31300336

Group type: EXPERIMENTAL
Intervention: Ringing the bell on the final day of RT
Number of subjects: 210

Group type: COMPARATOR
Intervention: Control group (no bell ringing)
Number of subjects: 210
Study: 27840326

Group type: EXPERIMENTAL
Intervention: SYNERGY stent
Number of subjects: 263

Group type: COMPARATOR
Intervention: PROMUS Element Plus stent
Number of subjects: 263
Study: 25709055

Group type: EXPERIMENTAL
Intervention: Enhanced Exercise Therapy
Number of subjects: 30

Group type: COMPARATOR
Intervention: Self-guided therapy
Number of subjects: 30
Study: 24361543

Group type: EXPERIMENTAL
Intervention: Visual search attentional bias modification (ABM)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control condition (placebo training versions)
Number of subjects: 16
Study: 21724950

Group type: EXPERIMENTAL
Intervention: Tablet form II of semagacestat (140 mg)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Semagacestat (140 mg) administered fed or fasting
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Semagacestat (140 mg) at different times of dosing (morning fasting, evening fasting)
Number of subjects: 41